Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.39 |
| ▸ | ITGAV | P06756 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17009347 | 1.00 | POLB (0.46) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL6127212 | 1.00 | POLB (0.46) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL6127110 | 1.00 | POLB (0.46) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL6122200 | 1.00 | POLB (0.46) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL20530282 | 1.00 | POLB (0.46) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL4700500 | 0.96 | POLB (0.43) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL7900077 | 0.96 | HPGD (0.44) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL24119265 | 0.95 | POLB (0.47) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL7901816 | 0.93 | POLB (0.45) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL4698454 | 0.93 | POLB (0.42) | POLBHPGDTRPM8GAATAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1071680-B1 | N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | ENCYSIVE PHARMACEUTICALS INC (US) | 2008-07-23 | — | — | EP | claimed |
| US-6194448-B1 | ANTIINFLAMMATORY AGENTS; ASTHMA; RHEUMATIC DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION | 2001-02-27 | — | — | US | claimed |
| US-20250206825-A1 | COMPOSITION FOR PREVENTING OR TREATING MYOCARDITIS, COMPRISING VLA-4 INHIBITOR | OSAKA UNIVERSITY (JP) | 2025-06-26 | — | — | US | disclosed |
| WO-2025058075-A1 | RADIOACTIVE POSITRON-EMITTING NUCLIDE CARBON-11 LABELED COMPOUND AND RADIOACTIVE COMPOSITION | 国立大学法人大阪大学 | 2025-03-20 | — | — | WO | disclosed |
| EP-4491196-A1 | COMPOSITION FOR PREVENTING OR TREATING MYOCARDITIS, COMPRISING VLA-4 INHIBITOR | OSAKA UNIVERSITY (JP) | 2025-01-15 | — | — | EP | disclosed |
| CN-118871130-A | Compositions for preventing or treating myocarditis comprising VLA-4 blocking substance | 国立大学法人大阪大学 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023196342-A1 | α4β1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023171789-A1 | COMPOSITION FOR PREVENTING OR TREATING MYOCARDITIS, COMPRISING VLA-4 INHIBITOR | 国立大学法人大阪大学 | 2023-09-14 | — | — | WO | disclosed |
| EP-1071680-B1 | N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | ENCYSIVE PHARMACEUTICALS INC (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20050222193-A1 | Novel combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-10-06 | — | — | US | disclosed |
| WO-2005074932-A1 | THE USE OF (S) - PANTOPRAZOLE MAGNESIUM FOR THE TREATMENT OF AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050165041-A1 | Combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1517706-A2 | COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA Pharma AG (DE) | 2005-03-30 | — | — | EP | disclosed |
| EP-1506016-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA Pharma AG (DE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003094967-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003094968-A2 | COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
| US-6194448-B1 | ANTIINFLAMMATORY AGENTS; ASTHMA; RHEUMATIC DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206825-A1 | COMPOSITION FOR PREVENTING OR TREATING MYOCARDITIS, COMPRISING VLA-4 INHIBITOR | FABP3, TNNI3, MYLK2 | POLB 4701/4885HPGD 4581/4885TRPM8 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.